ClinicalTrials.gg
Not yet recruitingNCT07534163BREATHE IIIUpdated Apr 16, 2026

III Brazilian Registry of Heart Failure

An observational study in Heart Failure, sponsored by Hospital do Coracao. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-16.

Sponsored by Hospital do Coracao · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,000
Ages
18 Years and older
Sex
All
01

Study summary

BREATHE III is a prospective, multicenter, observational registry designed to provide contemporary insights into the epidemiological, clinical, and prognostic characteristics of patients hospitalized with acute heart failure (AHF) in Brazil, including those with decompensated heart failure or new-onset ventricular dysfunction during acute myocardial infarction.

Recent evidence, such as the STRONG-HF trial, has demonstrated the prognostic benefit of rapid initiation and up-titration of guideline-directed medical therapy (GDMT) in patients with heart failure with reduced ejection fraction (HFrEF). However, prior phases of the BREATHE registry did not evaluate the timing of therapeutic optimization or barriers to implementing these strategies. Additionally, the therapeutic landscape of heart failure has evolved substantially in recent years, with the introduction of novel pharmacological agents, expanded indications for existing therapies, and new treatment options for heart failure with preserved ejection fraction (HFpEF).

BREATHE III aims to address these knowledge gaps by systematically assessing, over a 12-month follow-up, patient characteristics, treatment patterns, adherence to guideline-recommended therapies, time to treatment optimization, and clinical outcomes. The study will also identify barriers to the implementation and titration of evidence-based therapies, evaluate regional variations in care, and describe contemporary management practices across public and private healthcare settings in Brazil.

The results of this registry are expected to inform strategies to improve quality of care, optimize resource allocation, and guide future interventions aimed at reducing morbidity and mortality associated with heart failure in Brazil.

02

Conditions studied

  • Heart Failure

Browse trials for

03

In context

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

This study's planned enrollment of 2,000 is above the median of 200 across 1,987 observational studies indexed under Heart Failure.

Browse Heart Failure studies →

Lead sponsor

Hospital do Coracao is the lead sponsor of 67 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study will include adult patients (≥18 years) admitted to public and private hospitals in Brazil with acute heart failure-related presentations. Eligible participants comprise two main groups: (1) patients hospitalized for acute myocardial infarction (AMI) who develop newly identified left ventricular systolic dysfunction during hospitalization (LVEF ≤40), limited to up to 25% of the total study population; and (2) patients admitted with a primary diagnosis of decompensated heart failure, regardless of ejection fraction, defined according to the universal criteria for heart failure. In patients with heart failure with preserved ejection fraction (HFpEF), additional characterization will include H2FPEF and HFA-PEFF scores.

Patients will be excluded if they decline participation during the informed consent process, have undergone surgical myocardial revascularization within the previous month, present with heart failure secondary to sepsis, or are admitted with cardiogenic shock.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Adult patients (≥ 18 years) admitted to public and private hospitals with one of the two clinical conditions below:

  • Admission for AMI (Acute Myocardial Infarction) presenting with reduced during hospitalization (LVEF ≤ 40%) and which had not been previously identified (limit of 25% of the study sample included by this criterion)
  • Primary diagnosis of decompensated HF (regardless of ejection fraction), with the HF diagnosis established according to the universal definition of heart failure. In cases of HF with HFpEF, in addition to the data from the universal heart failure criteria, H2FPEF and HFA PEFF data will be collected.

Exclusion criteria

Exclusion Criteria

  • Refusal to participate in the study during the process;
  • Surgical myocardial revascularization in the last month;
  • Heart failure secondary to sepsis (sepsis as the origin of heart failure);
  • Cardiogenic shock.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. All-cause mortality

    All cases of death

    Time frame: 12 months

Secondary outcomes

  1. Length of hospital stay

    Duration of hospitalization

    Time frame: 12 months

  2. Composite outcome of death and rehospitalization

    Death or new hospitalization during follow-up

    Time frame: 12 months

  3. General rehospitalization, rehospitalization due to heart failure and emergency visits

    All-cause of rehospitalization, rehospitalization due to heart failure and emergency visits

    Time frame: 12 months

  4. Cardiovascular death

    Death due to cardiovascular causes

    Time frame: 12 months

  5. Composite outcome of cardiovascular death and rehospitalization due to heart failure

    Death to cardiovascular cause or rehospitalization due to heart failure

    Time frame: 12 months

  6. Proportion of patients receiving interventions with proven benefit demonstrated by different indicators of quality of care (at target dose)

    Percentage of patients receiving guideline-directed therapies

    Time frame: 12 months

  7. Quality of life according to the Minnesota Living with Heart Failure Questionnaire (MLHFQ)

    Assessment of Minnesota Living with Heart Failure Questionnaire (MLHFQ)

    Time frame: 12 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • DE Albuquerque DC, DE Barros E Silva PGM, Lopes RD, Hoffmann-Filho CR, Nogueira PR, Reis H, Nishijuka FA, Martins SM, DE Figueiredo Neto JA, Pavanello R, DE Souza Neto JD, Danzmann LC, Gemelli JR, Rohde LEP, Hernandes ME, Rivera MAM, Simoes MV, Dos Santos ES, Canesin MF, Zilli AC, Santos RHN, Jesuino IA, Mourilhe-Rocha R, Moura LZ, Marcondes-Braga FG, Mesquita ET; BREATHE INVESTIGATORS. In-Hospital Management and Long-term Clinical Outcomes and Adherence in Patients With Acute Decompensated Heart Failure: Primary Results of the First Brazilian Registry of Heart Failure (BREATHE). J Card Fail. 2024 May;30(5):639-650. doi: 10.1016/j.cardfail.2023.08.014. Epub 2023 Aug 28. PubMed 37648061 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Oct 2028, 29 months later.

Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 29 months is below that.

Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2026
First posted
Apr 16, 2026
StartEst.
Apr 20, 2026
Primary completionEst.
Oct 1, 2028
CompletionEst.
Oct 1, 2028
Last update
Apr 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07534163
Lead sponsor
Hospital do Coracao
Collaborators
Brazilian Society of Cardiology
Responsible party
Sponsor
First posted
Apr 16, 2026
Start date
Apr 20, 2026 (estimated)
Primary completion
Oct 1, 2028 (estimated)
Completion
Oct 1, 2028 (estimated)
Last update
Apr 16, 2026

Study contacts

Pedro Gabriel M de Barros e Silva, MD, MHS, PhD
Contact
pgmelo@hcor.com.br
113889-3939

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion